ClinicalTrials.gg
CompletedNCT05861128Updated Sep 24, 2026

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

A Phase 3 interventional study of Jaktinib in Ankylosing Spondylitis, sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
207
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Enrollment
23rd of 62
207 · median 150
Started
2023
with 6 others
Phase 3
18 of 76
4 open now
Registered
49th of 76
by date
Lead sponsor
3 of 76
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 23rd largest by enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 18 in phase 3, and was the 49th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Jaktinib is safe and effective in participants with active ankylosing spondylitis.

03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The investigators concluded that the participants continued to benefit from treatment with Jaktinib.
  • The participants have been fully informed and voluntarily signed .
  • The participants completed the ZGJAK029 study for 16 weeks of treatment and visitation and had good compliance.
  • The interval between the participants' first dose and the last dose of ZGJAK029 ≤ 4 weeks.

Exclusion criteria

Exclusion Criteria:

  • There were any grade ≥3 adverse events within 4 weeks prior to enrollment and no return to grade 1 or normal.
  • Within 4 weeks prior to enrollment, participants had the following infectious diseases: tuberculosis infection requiring treatment; -positive, syphilis, infection, infection.
  • The investigators considered participants unsuitable for this study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
207 participants (actual)

Study arms

  • Experimental
    Jaktinib 100mg BID (twice daily)

    Drug: Jaktinib

Interventions

  • Participants will receive 100 mg Jaktinib orally twice daily for 32 weeks

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Related Discontinuations at 32 Weeks

    Treatment-emergent AEs were events that occurred between first dose of study drug and up to 32 weeks that were absent before treatment or that worsened relative to pretreatment state.

    Time frame: Baseline up to Week 32

Secondary outcomes

  1. Percentage of Participants Achieving ASAS20 Response at Week 4, 8, 12, 16,20,24,28 and 32

    ASAS20 assess 4 domains: PGA of Disease (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], high score=more disease activity), total back pain (scale of 0 \[no pain\] to 10 \[most severe pain\], high score=more severity), Function (BASFI; participant's level of ability on scale of 0 \[easy\] to 10 \[impossible\], low score= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6-item questionnaire measure disease activity on a scale of 0 \[none\] to 10 \[severe\], high score=more disease activity). ASAS20 response: \>= 20% improvement from baseline in disease activity and absolute change of \>=1 unit in \>=3 domains and no worsening of \>=20% and an absolute change of \>=1 unit in remaining domain.

    Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32

  2. Percentage of Participants Achieving ASAS40 Response at Week 4, 8, 12, 16,20,24,28 and 32

    ASAS40 assessed 4 domains: the "PGA" (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), total back pain (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (from BASFI: assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (morning stiffness, Mean of Q5 and Q6 of BASDAI defined as 6 item questionnaire: measures disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity). ASAS40 response: \>=40% and \>=2 units improvement in \>=3 domains and no worsening at all in the remaining domain.

    Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32

  3. Change From Baseline in Patient's Assessment of Spinal Pain: Total Back Pain at Week 4, 8, 12, 16,20,24,28 and 32

    Participants marked their level of total back pain on a numerical rating scale (NRS) ranged from 0 (no pain) to 10 (most severe pain), with higher scores indicated more severe pain.

    Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32

  4. Percentage of Participants Achieving ASAS 5/6 Response at Week 4, 8, 12, 16,20,24,28 and 32

    ASAS 5/6 consists of 6 domains: 4 used in ASAS20 - PGA (assess disease activity on a scale of 0 \[not active\] to 10 \[very active\], higher score=more disease activity), Spinal Pain (total back pain) (on a scale of 0 \[no pain\] to 10 \[most severe pain\], higher score=more severity), Function (using BASFI which assess participant's level of ability on a scale of 0 \[easy\] to 10 \[impossible\], lower scores= better functional health) and Inflammation (using BASDAI, mean of Q 5 and 6, which assess disease activity on a scale of 0 \[none\] to 10 \[severe\], higher score=more disease activity), CRP (was measured in mg per liter) and Spinal mobility was measured in centimeter and calculated as mean of right and left measurements of lateral spinal flexion from BASMI. ASAS 5/6: defined as \>=20% improvement in at least 5 domains.

    Time frame: Baseline, Week 4, 8, 12, 16,20,24,28 and 32

07

Study locations

1 site
  • Renji Hospital
    Shanghai, Shanghai Municipality 200001, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Mar 2026, 27 months.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 27 months is above that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2023
First posted
May 16, 2023
StartActual
Nov 10, 2023
Primary completionActual
Mar 4, 2026
CompletionActual
Mar 4, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05861128
Responsible party
Sponsor
First posted
May 16, 2023
Start date
Nov 10, 2023
Primary completion
Mar 4, 2026
Completion
Mar 4, 2026
Last update
Sep 24, 2026

Study contacts

Chunde Bao
principal investigator · RenJi Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Jaktinib

Start the discussion